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Abstract
Background: Obesity is a main threat to public health in the Western world and is associated
with diseases such as diabetes mellitus and coronary heart diseases. Up to now a minority of
research studied the relation between obesity and the use of primary health care. In the
Netherlands the general practitioner (GP) is the main primary health care provider. The objective
of this article is to evaluate GP consultation and prescription of drugs in moderate and severely
overweight (obese) persons in the Netherlands.
Methods: Data were used from a representative survey of morbidity in Dutch general practice in
2001. Our study sample consisted of 8,944 adult respondents (18+ years) who participated in an
extensive health interview. Interview data were linked to morbidity and prescription registration
data from 95 general practices where respondents were listed. Body mass index (BMI) was
calculated using self-reported height and weight. Analyses were controlled for clustering within
practices as well as for socio-demographic and life style characteristics.
Results: Obesity (BMI ≥ 30 kg/m2) was observed in 8.9% of men and 12.4% of women; for
moderate overweight (BMI 25-<30 kg/m2) these percentages were 42.2% and 30.4% respectively.
Obese men and women were more likely to consult their GP than persons without overweight.
This especially holds for diseases of the endocrine system, the cardiovascular system, the
musculoskeletal system, the gastro-intestinal system, and skin problems. Related to this, obese men
and women were more likely to receive drugs for the cardiovascular system, the musculoskeletal
system, alimentary tract and metabolism (including, for example, antidiabetics), and
dermatologicals, but also antibiotics and drugs for the respiratory system. For moderately
overweight men and women (BMI 25-<30 kg/m2) smaller but significant differences were found for
diseases of the endocrine system, the cardiovascular system, and the musculoskeletal system.
Conclusion:  Obesity increases the workload of Dutch general practitioners and the use of
prescribed medication. The current increase in the prevalence of obesity will further increase the
use of health care and related costs. Since a large majority of Dutch persons visit their GP over the
course of one year, GPs' potential role in effective prevention strategies cannot be denied.
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Background
Obesity is one of the main threats to public health in the
Western world [1,2]. It is a well-known risk factor for cor-
onary heart diseases and type 2 diabetes mellitus [e.g. [3-
10]]. Other health problems such as musculoskeletal dis-
orders, psychological problems, osteoarthritis, cancer,
and respiratory problems have been related to obesity as
well [11-17]. Obesity decreases life expectancy with
almost seven years [18] and obese persons have an
impaired quality of life [19]. Costs of obesity in various
countries have been estimated at 4 to 8% of total health
care costs [20-24]. In the Netherlands about 40% of the
population is overweight (BMI > 25 kg/m2) and about
10% of the total population is obese (BMI ≥ 30 kg/m2)
[25]. Although the prevalence of obesity in the Nether-
lands is still lower than in most other European countries
[2,26] and the USA [27], an increase has been observed
over the last decade [28] This trend is worrying and
prompted the National Health Council of the Nether-
lands to urge for further research with respect to assessing
trends and examining effective prevention strategies [28].
Up to now, a minority of studies focused on the associa-
tion between obesity and the use of primary care. In
Anglo-Saxon countries, where the problem of obesity is
even more abound than in the Netherlands, it was found
that obesity increased the use of primary health care as
well as the use of prescribed medication [24,29,30]. These
studies, however, did not include information on persons
with modest overweight. Moreover, they did not take into
account other life style factors such as smoking habits,
exercising, and alcohol consumption. In the Netherlands,
extra need for health care caused by obesity and over-
weight will primarily be handled by general practitioners.
Dutch GPs have an important role within the health care
system since they perform a gatekeeper role. All Dutch
inhabitants are listed with a general practice and the GP is
the first one to be consulted for health problems. Dutch
GPs deal with 96% of all problems themselves; only in
4% of their consultations GPs refer their patients to a
medical specialist or to other primary care providers [31].
Prescribing drugs is the most common treatment in Dutch
general practice [31,32] and it generates considerable cost:
almost  € 3.8 billion in 2001 [33]. GPs prescribe the
majority of medication in the Netherlands [34].
It is not clear what the extra need for GP care and associ-
ated treatment among obese and moderately overweight
patients in the Netherlands is. In this study we compare
GP consultation and drug prescribing in obese and mod-
erately overweight Dutch adults (18+ years) with GP con-
sultation and drug prescribing in Dutch adults without
overweight taking into account socio-demographic char-
acteristics and other life style factors.
Methods
Data were used from the Second Dutch National Survey of
General Practice in 2001 [35]. This nationwide survey was
conducted by the Netherlands Institute for Health Services
Research (NIVEL) in cooperation with the National Insti-
tute for Public Health. At first, practices already participat-
ing in the Dutch National Information Network of
General Practice (LINH) were invited to participate in this
study because of their experience in the use of electronic
medical records [36]. Sixty-one LINH-practices agreed to
participate. To recruit more practices a mailing was sent
out to a sample of GPs stratified with respect to type of
practice, level of urbanisation, and region. Stratification
was used to increase the representativeness of the partici-
pants. Another 43 practices were willing to participate.
The 104 general practices compromised 195 GPs. The par-
ticipating GPs were representative for the Dutch GP pop-
ulation on age, sex, part-time/fulltime working,
urbanisation level, and region. Single-handed practices
were under-represented.
In the Netherlands, all inhabitants are listed in a general
practice. The patient population of the 104 practices was
representative for the Dutch population as a whole
[35,36]. Approximately 5% of the Dutch-speaking listed
patients in the 104 practices were asked to participate in
an extensive health interview (n = 19,685). A letter from
the GP accompanied the invitations. Selection for the
interview was random, with a fixed target per full-time GP.
The response rate to the interview was 64.5% and the total
number of respondents was 12,699; 9,685 respondents
were 18 years or older. The distribution of the respond-
ents according to age, gender and residence was compara-
ble to that of the Dutch population [35]. Privacy of the
participating persons was guaranteed and in accordance
with Dutch legislation. Patients were informed about the
study prior to the start of the data collection via a personal
letter written by their GP and by announcements in the
practice [35].
Trained interviewers interviewed respondents at home.
The interviews were evenly distributed among four con-
secutive 3-months periods to correct for seasonal influ-
ences. Items used for this study included self-reported
weight and height, socio-economic status, and life style
characteristics. Interview data of the respondents were
linked to their morbidity and prescription data as regis-
tered by their GP in 2001. Over the course of one year,
GPs who participated in the survey registered all contacts
with their patients. This included face-to-face consulta-
tions as well as telephone consultations and repeat pre-
scriptions. Every single health problem presented within a
consultation was coded by the GP using the International
Classification for Primary Care (ICPC) [37]. When a
patient presented two complaints within one consulta-BMC Family Practice 2006, 7:43 http://www.biomedcentral.com/1471-2296/7/43
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tion, these were coded as two separate (sub)consultations.
Different consultations for the same health problem were
clustered into disease episodes. Medical students who
were trained by NIVEL staff members did this after the
data collection. GPs also registered all prescriptions using
the Anatomical Therapeutical Chemical (ATC) coding sys-
tem [38]. Therefore it is known for every patient how
often he or she contacted the GP and for which health
problems. Moreover, it was known how many prescrip-
tions the patient received and what type of medication it
was. Patients from nine practices were excluded because
of insufficient quality of the morbidity and/or prescrip-
tion registration data (n = 543 patients). Another 198
respondents were excluded because of incomplete data on
weight and/or height or a BMI of < 15 kg/m2. Included in
the analyses were 8,944 respondents with complete data
(men: 4,048; women: 4,896).
As a measure for overweight and obesity, body mass index
(BMI) was used. BMI was based on self-reported weight
and height. Three groups were distinguished: without
overweight (BMI < 25 kg/m2), moderately overweight
(BMI 25- < 30 kg/m2), and obese (≥ 30 kg/m2). GP con-
sultation was assessed in different ways. The first measure
was whether or not the patient visited the GP during the
year of registration. Moreover, the number of consulta-
tions with the GP was assessed. As stated before, every
consultation was coded according to the ICPC. This clas-
sification contains different chapters, each referring to a
group of diseases. When a patient consulted the GP for
hypertension, this patient was coded as having consulted
the GP for a complaint/disease in ICPC-chapter K (cardi-
ovascular diseases).
The assessment of drug prescribing was comparable to
that of GP consultation. The first assessment referred to
the question whether or not the patient received at least
one prescription in 2001. The number of prescriptions per
patient was also assessed. The ATC-classification system
distinguishes drugs for different diseases. For each ATC-
chapter it was assessed whether the patient got at least one
prescription (versus none) within the respective chapter.
Since both obesity and morbidity are associated with
lower socio-economic status, age, and lifestyle [39], anal-
yses were controlled for these factors. Included variables
were: age, type of health insurance (private/public), place
of residence (urban/rural), educational level (low/mid-
dle/high), smoking (current smoker/non-smoker), alco-
hol consumption (no alcohol consumption/1–2 glasses
per day/more than 2 glasses per day) and number of days
per week that respondents spends at least 30 minutes in
exercise activities such as walking, cycling, and gardening
(never/1 to 3 days per week/4 to 6 days per week/every
day).
Three categories for BMI were distinguished in all analy-
ses: without overweight (BMI < 25 kg/m2), moderately
overweight (BMI 25- <30 kg/m2), and obese (≥ 30 kg/
m2). Moreover, men and women were analysed sepa-
rately. We compared socio-demographics and life style
characteristics for the three BMI-categories. Differences
between BMI-categories were tested with chi-square tests.
Chi-square tests were also used to test differences between
BMI-categories in the proportion of respondents who
consulted their GP and the proportion of respondents
who received a prescription. We used multilevel logistic
regression to calculate the odds of visiting the GP for a cer-
tain ICPC-code. Reference category in these analyses was
the BMI-category "no overweight". The multilevel design
was chosen because of the nested structure of the data –
our patients were sampled from general practices -. It was
also used to assess differences between BMI-categories in
drug prescribing for specific ATC-chapters. All multilevel
logistic regressions were controlled for sociodemographic
and life style variables.
Results
Prevalence of obesity and overweight
Obesity was reported by 8.9% of male and 12.4% of
female respondents (Table 1). Men were more often mod-
erately overweight than women: 42.2% and 30.4% respec-
tively. Both male and female respondents with moderate
overweight and obesity were less well educated, more
often had public health insurance, spent less time in exer-
cising, but had a lower alcohol consumption compared to
respondents without overweight. Especially in the age cat-
egory 55–74 years women more often were obese, while
for men the age category 35–54 years was overrepresented
among the obese group as well. Overweight and obese
women smoked less often than women without over-
weight.
GP consultation
The percentage of respondents who consulted their GP at
least once in 2001 was highest among obese respondents
and lowest among respondents with BMI < 25 kg/m2.
While 82.2% of obese men consulted their GP in 2001,
72.7% of men without overweight did so (Figure 1). For
women the difference was smaller: 90% of obese women
and 85.6% of women without overweight contacted their
GP in 2001.
The number of visits to the GP in 2001 was higher in
obese men compared to men without overweight (Figure
2). The difference was highest among the eldest: obese
men in this age category visited their GP twice as often
compared to their peers without overweight. Obese
women in all age categories, except the eldest, consulted
their GP more often than women without overweight.BMC Family Practice 2006, 7:43 http://www.biomedcentral.com/1471-2296/7/43
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Table 2 and Table 3 show that, for both men and women,
differences in GP consultation can be attributed to some
categories of diseases in particular. Differences in consul-
tation rates between respondents without overweight and
obese respondents were most profound for diseases of the
endocrine system, the cardiovascular system, the muscu-
loskeletal system, the gastro-intestinal system, skin prob-
lems and, in women, diseases of the respiratory system.
These differences remained significant after controlling
for sociodemographic characteristics and life style factors.
For diseases of the cardiovascular and endocrine system
differences between obese and non-overweight respond-
ents were larger in men than in women.
Moderately overweight men and women (BMI 25- <30 kg/
m2) were more likely to consult their GP for cardiovascu-
lar problems as well as musculoskeletal problems and dis-
eases of the endocrine system than non-overweight
persons but less likely than obese respondents.
Drug prescribing
The percentage of respondents who received a prescrip-
tion in 2001 was highest among obese respondents and
lowest among those without overweight. Differences were
larger for men than for women (Figure 1). Considerable
differences existed between the average numbers of pre-
scriptions for the three BMI-categories (Figure 3),
Table 1: Distributions of sociodemographic and life style characteristics among BMI-categories; men and women (N = 8,944)a)
Men Women
BMI < 25 kg/
m2 (n = 1980)
BMI 25- <30 kg/
m2 (n = 1707)
BMI = 30 kg/
m2 (n = 361)
BMI < 25 kg/
m2 (n = 2800)
BMI 25- <30 kg/
m2 (n = 1488)
BMI = 30 kg/
m2 (n = 608)
Age p < 0.001 p < 0.001
< 35 years 31.5 14.2 13.0 28.9 13.1 12.5
35–54 40.3 46.3 51.5 44.9 43.3 43.6
55–74 21.6 33.0 31.3 19.5 33.4 36.0
75plus 6.6 6.4 4.2 6.8 10.2 7.9
Educational level p < 0.001 p < 0.001
Low 28.8 35.9 46.0 28.5 44.8 55.9
Middle 45.0 41.4 40.7 48.1 40.4 34.2
High 26.2 22.7 13.3 23.3 14.7 9.9
Health insurance p = 0.005 p < 0.001
Public 58.8 58.2 67.3 68.8 73.9 79.8
Private 41.2 41.8 32.7 31.2 26.1 20.2
Place of residence p = 0.008 ns
Urban 35.1 30.2 33.5 35.9 33.6 34.9
Rural 64.9 69.8 66.5 64.1 66.4 65.1
Smoking p = 0.001 p < 0.001
Non-smoker 60.9 66.9 64.0 70.8 75.9 76.6
Current smoker 39.1 33.1 36.0 29.2 24.1 23.4
Alcohol consumption p < 0.001 p < 0.001
None 14.8 17.5 24.3 28.2 37.0 45.0
s 1–2 glass p/day 58.8 57.8 51.7 64.5 56.4 50.8
> 2 glasses p/day 26.4 24.7 24.0 7.3 6.6 4.2
Exercise (> 30 
minutes p/day)
p = 0.034 p < 0.001
< 1 day p/week 10.2 10.5 15.6 12.5 17.5 21.6
1–3 days p/week 24.7 26.8 25.6 21.0 19.5 21.8
4–6 days p/week 24.2 22.0 22.8 21.6 20.8 20.6
all days 40.8 40.8 36.1 45.0 42.2 36.0
% of all men/women 48.9 42.2 8.9 100% 57.2 30.4 12.4 100%
a) significance test: Pearson Chi-square test, ns = not significant (p > 0.05)BMC Family Practice 2006, 7:43 http://www.biomedcentral.com/1471-2296/7/43
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although there were some differences between men and
women and for different age categories. The largest differ-
ence was found in women aged 55–74 years. Non-over-
weight women in this age category received 9.9
prescriptions while their obese peers received almost
twice as many prescriptions: 18.0.
In almost all ATC-categories a significant difference
between the BMI-categories was observed in the percent-
age of respondents who received a prescription (Table 4
and Table 5). After controlling for socio-demographic and
life style characteristics it proved that GPs prescribed more
often drugs for the cardiovascular system, drugs for the
musculoskeletal system, drugs for the alimentary tract and
metabolism (including for example antidiabetics), and
dermatologicals to obese men and women than to non-
overweigh respondents. The prescription of these drugs is
related to the diseases for which obese respondents had a
higher probability of consulting their GP. Obese respond-
ents were more likely to receive prescriptions for antibiot-
ics and drugs for the respiratory system as well.
Moderately overweight men and women (BMI 25- <30 kg/
m2) were more likely to get prescribed drugs for the cardi-
ovascular system and for the musculoskeletal system.
Moreover, moderately overweight men more often
received drugs for blood and blood forming organs com-
pared to men without overweight, while moderately over-
weight women received more prescriptions for drugs of
the respiratory system than non-overweight women.
Discussion
Comparison with previous research
The results of this cross-sectional study show that obesity
increases the workload of Dutch general practitioners.
Independent of differences in gender, age, social status
and life style, obese Dutch persons are more likely to con-
sult their GP and need pharmacotherapeutical care more
often. This was also found in countries with a higher pro-
portion of obese inhabitants than the Netherlands: the
UK and the US [24,29,30]. Differences in GP consultation
are largest for diseases of the endocrine system, the cardi-
ovascular system and the musculoskeletal system, which
is in line with findings of previous epidemiological
research on the positive association between obesity and
cardiovascular diseases, type 2 diabetes mellitus and oste-
oarthritis (as described in the introductory part of this
contribution). Moreover, obese persons were more likely
to consult their GP for skin problems and gastro-intestinal
problems. Drug prescribing was largely related to the mor-
bidity pattern, as was also found in a study published by
the Counterweight Team [24]. However, obese persons
were more likely to use antibiotics and drugs for respira-
tory system, while they did not consult the GP more often
for respiratory problems. For this latter group of drugs, it
may well be that obese persons consulted the medical spe-
cialist, but received their (repeat) prescriptions from their
GP. Obese persons were not likely to present more psy-
Average number of visits to GP by age and BMI in 2001 (N =  8,944) Figure 2
Average number of visits to GP by age and BMI in 2001 (N = 
8,944).
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Table 3: Differences in GP consultation of women in different BMI-categories: bivariate and multilevel analyses
Bivariate analyses a) Percentage that visited GP for ICPC-
chapter
Multilevel logistic regression b,c) Adjusted 
odds ratios [95% BI]
ICPC-Chapter BMI < 25 kg/
m2 (n = 2800)
BMI 25- <30 kg/
m2 (n = 1488)
BMI = 30 kg/
m2 (n = 608)
BMI 25- <30 kg/m2 BMI ≥ 30 kg/m2
General (A) 14.0 14.0 16.0 ns 0.92 [0.76–1.11] 1.03 [0.80–1.33]
Blood and blood forming organs (B) 4.0 3.7 4.1 ns 0.85 [0.60–1.19] 0.86 [0.54–1.37]
Gastro-intestinal (D) 15.7 17.5 23.4 p < 0.001 0.99 [0.83–1.18] 1.35* [1.08–1.69]
Eye (F) 8.2 10.1 10.0 ns 0.99 [0.79–1.24] 1.02 [0.75–1.39]
Ear (H) 10.6 11.6 12.3 p = 0.031 0.96 [0.78–1.18] 1.03 [0.78–1.36]
Cardiovascular system (K) 15.4 26.3 35.4 p < 0.001 1.37* [1.15–1.62] 2.16* [1.73–2.69]
Musculoskeletal system (L) 37.1 44.8 51.3 p < 0.001 1.22* [1.06–1.39] 1.52* [1.25–1.84]
Nervous system (N) 9.6 11.4 13.2 p = 0.017 1.08 [0.86–1.32] 1.20 [0.91–1.58]
Psychic problems (P) 15.3 16.5 15.5 ns 0.96 [0.80–1.15] 0.83 [0.64–1.07]
Respiratory system (R) 29.9 34.7 42.1 p < 0.001 1.08 [0.94–1.24] 1.41* [1.17–1.71]
Skin (S) 29.9 30.0 36.2 p = 0.007 0.99 [0.86–1.15] 1.25* [1.03–1.52]
Endocrine system (T) 5.6 11.7 17.9 p < 0.001 1.62* [1.28–2.05] 2.52* [1.91–3.33]
Urinary tract (U) 9.4 11.1 13.7 p = 0.005 1.00 [0.81–1.23] 1.19 [0.90–1.57]
Pregnancy, anticonception (W) 20.2 12.2 10.0 p < 0.001 1.09 [0.88–1.35] 0.81 [0.58–1.14]
Reproductive system women (X) 25.9 21.6 28.6 p = 0.003 0.93 [0.79–1.09] 1.19 [0.96–1.47]
Social problems (Z) 4.0 3.0 4.3 ns 0.70 [0.49–1.02] 1.00 [0.64–1.58]
a) significance test: Pearson Chi-square test, ns = not significant (p < 0.05), ns = not significant (p > 0.05)
b) Multilevel logistic regression, odds ratios are corrected for age, sex, educational level, type of health insurance, residence, smoking, alcohol 
consumption and exercising
c) reference in multilevel logistic regression is BMI < 25
* p < 0.05
Table 2: Differences in GP consultation of men in different BMI-categories: bivariate and multilevel analyses
Bivariate analyses a) Percentage that visited GP for ICPC-
chapter
Multilevel logistic regression b,c) Adjusted 
odds ratios [95% BI]
ICPC-Chapter BMI < 25 kg/
m2 (n = 1980)
BMI 25- <30 kg/
m2 (n = 1707)
BMI = 30 kg/
m2 (n = 361)
BMI 25- <30 kg/m2 BMI ≥ 30 kg/m2
General (A) 8.8 10.5 10.2 ns 1.18 [0.94–1.48] 1.08 [0.74–1.59]
Blood and blood forming organs (B) 2.0 1.5 1.9 ns 0.63 [0.38–1.05] 0.76 [0.33–1.75]
Gastro-intestinal (D) 13.2 15.0 19.7 p = 0.004 1.01 [0.84–1.23] 1.37* [1.02–1.84]
Eye (F) 7.0 7.1 7.5 ns 0.92 [0.71–1.19] 0.93 [0.60–1.44]
Ear (H) 8.9 11.5 10.8 ns 1.17 [0.94–1.45] 1,08 [0.74–1.56]
Cardiovascular system (K) 13.9 21.1 31.6 p < 0.001 1.32* [1.08–1.61] 2.90* [2.16–3.88]
Musculoskeletal system (L) 28.0 34.9 38.5 p < 0.001 1.32* [1.14–1.52] 1.46* [1.15–1.86]
Nervous system (N) 5.1 6.5 8.0 p = 0.043 1.22 [0.92–1.62] 1.45 [0.61–3.47]
Psychic problems (P) 8.9 9.5 11.6 ns 1.09 [0.87–1.38] 1.33 [0.92–1.92]
Respiratory system (R) 24.7 27.3 31.6 p = 0.014 1.00 [0.85–1.16] 1.18 [0.91–1.52]
Skin (S) 25.5 27.7 32.7 p = 0.014 1.07 [0.92–1.24] 1.30* [1.02–1.67]
Endocrine system (T) 5.8 11.7 19.7 p < 0.001 1.79* [1.40–2.30] 3.44* [2.45–4.82]
Urinary tract (U) 3.7 4.2 3.9 ns 0.91 [0.65–1.29] 0.79 [0.42–1.46]
Reproductive system men (Y) 6.6 7.0 6.1 ns 0.91 [0.70–1.18] 0.80 [0.49–1.28]
SSocial problems (Z) 2.0 2.2 1.4 ns 1.08 [0.67–1.73] 0.61 [0.24–1.58]
a) significance test: Pearson Chi-square test, ns = not significant (p < 0.05), ns = not significant (p > 0.05)
b) Multilevel logistic regression, odds ratios are corrected for age, sex, educational level, type of health insurance, residence, smoking, alcohol 
consumption and exercising
c) reference in multilevel logistic regression is BMI < 25
* p < 0.05BMC Family Practice 2006, 7:43 http://www.biomedcentral.com/1471-2296/7/43
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chological problems to their GP, while it has been sug-
gested that psychological problems and obesity are
associated [28]. Earlier research on the impact of obesity
on the use of primary health care did not include persons
with moderate overweight (BMI 25- < 30 kg/m2)
[24,29,30]. Moderately overweight persons consulted
their GP more often for diseases of the endocrine system,
cardiovascular diseases and musculoskeletal problems
and got more prescriptions related to these diseases than
persons without overweight, albeit differences with non-
overweight persons were clearly smaller than for obese
persons. It should be noted that we included persons (n =
173) with low BMI (< 18.5 kg/m2) in our reference cate-
gory. Albeit these persons tend to consult their GP more
often, additional bivariate and multivariate analyses
showed that there was hardly any significant difference
between them and persons with BMI 18.5–25 kg/m2 . Pre-
vious studies in this field did not assess men and women
separately [24,29,30]. Our results showed that there are
some differences between men and women, but these dif-
ferences are not striking.
Strengths and limitations
This study used cross-sectional data from almost 10,000
Dutch adult persons who were listed in 95 general prac-
tices. Data from a health interview were linked to data
from their GP's registration. The combination of such
extensive interview data combined with GP registration
data is unique. The extensive interview data made it pos-
sible to control the analyses for a large set of possible con-
founders such as smoking, alcohol consumption, and
exercising. Moreover, clustering within general practices
was taken into account in the multilevel analyses. Con-
trary to the Counterweight Project [24,30] our study was
not specifically developed to study the impact of obesity
on health care use. Therefore, it is not plausible to assume
a bias in the participation of general practitioners with
regard to the topic of our study. However, patients' partic-
ipation in the health interview may be biased. There was
a 34.5 percent non-response to the health interview. It has
been found that non-respondents more often have poorer
health [40]. Therefore, it may be well that obese and over-
weight persons more often refused to participate in the
interview.
Another limitation of the study is the use of self-reported
data on weight and height. A recent study by Ezzati et al
showed that women tend to underreport their weight
[41]. Men did not, but young and middle-aged men over-
report their height. Both phenomena lead to an underes-
timation of BMI. This would imply that the impact of
weight on the use of GP care and on drug prescribing is
underestimated in our study. However, Ezzati et al also
showed that the bias was larger in telephone interviews
compared to in-person interviews. Such face-to-face inter-
views clearly promote the validity of answers on self-
reported height and weight. The proportions of over-
weight and obese persons we found in our study were
almost comparable to those of Dutch studies where
weight and height were actually measured by the study
personnel [28].
Clinical implications
Almost all obese and moderately overweight persons con-
sult their GP at least once a year. Because of these high
consultation rates, GPs' potential role in weight manage-
ment, the prevention of complications of obesity, and
related use of health care is strong. Moreover, it can be
assumed that advice to lose weight is more effective if
linked to patients' health problems such as coronary heart
disease, musculoskeletal problems and diabetes mellitus.
However, up to now weight management is not embed-
ded in general practice. British researchers argued that
obesity is under-recognized in primary care [42]. There is
no reason to assume that this is different in the Nether-
lands. Attempts have been made to improve weight man-
agement in primary care in the UK, with some attempts
Average number of prescriptions received from GP by age  and BMI (N = 8,944) Figure 3
Average number of prescriptions received from GP by age 
and BMI (N = 8,944).
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Table 5: Differences in prescribed drugs for women in different BMI-categories: bivariate and multilevel analyses
Bivariate analyses a) Percentage that got prescribed for ICPC-
chapter
Multilevel logistic regression b,c)
Adjusted odds ratios [95% BI]
ATC-Chapter BMI < 25 kg/m2
(n = 1980)
BMI 25- <30 kg/m2
(n = 1707)
BMI = 30 kg/m2
(n = 361)
BMI 25- <30 kg/m2 BMI ≥ 30 kg/m2
Alimentary tract and metabolism 
(A)
16.7 23.4 30.4 p < 0.001 1.13 [0.96–1.34] 1.53* [1.24–1.90]
Blood and blood forming organs 
(B)
9.0 11.7 15.5 p < 0.001 0.90 [0.72–1.12] 1.16 [0.88–1.54]
Cardiovascular system (C) 15.1 28.8 37.8 p < 0.001 1.58* [1.33–1.88] 2.53* [2.02–3.16]
Dermatologicals (D) 23.4 24.5 32.4 p < 0.001 1.00 [0.85–1.16] 1.45* [1.18–1.77]
Genito urinary system and sex 
homones (G)
37.9 28.7 26.5 p < 0.001 1.03 [0.88–1.21] 0.87 [0.70–1.09]
Systemic hormonal preparations 
(H)
5.4 8.4 10.7 p < 0.001 1.23 [0.95–1.58] 1.53* [1.12–2.11]
Antiinfectives for systemic use (J) 28.9 36.9 42.1 p < 0.001 1.11 [0.96–1.28] 1.35* [1.12–1.64]
Antineoplastic and 
immunomodulating agents (L)
0.8 0.9 1.5 ns 0.97 [0.48–1.97] 1.61 [0.72–3.60]
Musculoskeletal system (M) 20.6 29.6 36.0 p < 0.001 1.38* [1.18–1.60] 1.75* [1.43–2.14]
Nervous system (N) 26.1 33.1 35.0 p < 0.001 1.09 [0.94–1.26] 1.15 [0.94–1.40]
Antiparasitic products (P) 1.5 0.9 1.5 ns 0.72 [0.39–1.35] 0.94 [0.41–2.16]
Respiratory system (R) 20.9 25.1 31.1 p < 0.001 1.23* [1.05–1.44] 1.62* [1.33–1.99]
Sensory organs (S) 9.7 11.6 11.8 ns 1.04 [0.85–1.29] 1.03 [0.78–1.38]
a) significance test: Pearson Chi-square test, ns= not significant (p < 0.05), ns = not significant (p > 0.05)
b) Multilevel logistic regression, odds ratios are corrected for age, sex, educational level, type of health insurance, residence, smoking, alcohol 
consumption and exercising
c) reference in logistic regression is BMI < 25
* p < 0.05
Table 4: Differences in prescribed drugs for men in different BMI-categories: bivariate and multilevel analyses
Bivariate analyses a) Percentage that got prescribed for ICPC-
chapter
Multilevel logistic regression b,c)
Adjusted odds ratios [95% BI]
ATC-Chapter BMI < 25kg/m2
(n = 1980)
BMI 25- <30 kg/m2
(n = 1707)
BMI = 30 kg/m2
(n = 361)
BMI 25- <30 kg/m2 BMI ≥ 30 kg/m2
Alimentary tract and metabolism 
(A)
14.0 16.9 25.2 p < 0.001 1.01 [0.83–1.22] 1.66* [1.24–2.21]
Blood and blood forming organs 
(B)
9.2 14.2 13.3 p < 0.001 1.29* [1.02–1.63] 1.23 [0.83–1.81]
Cardiovascular system (C) 14.6 25.2 32.1 p < 0.001 1.62* [1.34–1.97] 2.81* [2.09–3.77]
Dermatologicals (D) 18.9 22.1 26.3 p = 0.002 1.12 [0.95–1.32] 1.37* [1.05–1.80]
Genito urinary system and sex 
homones (G)
3.3 4.5 3.3 ns 1.11 [0.78–1.58] 0.84 [0.43–1.64]
Systemic hormonal preparations 
(H)
3.7 4.5 8.0 p = 0.001 1.01 [0.73–1.42] 1.79* [1.13–2.85]
Antiinfectives for systemic use (J) 21.6 27.5 32.4 p < 0.001 1.12 [0.95–1.31] 1.36* [1.04–1.77]
Antineoplastic and 
immunomodulating agents (L)
0.4 0.4 0.6 ns 0.95 [0.33–2.75] 1.20 [0.24–5.98]
Musculoskeletal system (M) 14.3 20.8 30.2 p < 0.001 1.43* [1.20–1.71] 2.18* [1.67–2.85]
Nervous system (N) 14.8 18.2 21.6 p = 0.001 1.12 [0.94–1.35] 1.30 [0.97–1.74]
Antiparasitic products (P) 0.8 0.8 1.7 ns 0.96 [0.45–2.01] 2.16 [0.82–5.64]
Respiratory system (R) 15.8 18.6 23.0 p < 0.001 1.12 [0.94–1.33] 1.40* [1.06–1.85]
Sensory organs (S) 7.9 8.6 9.4 ns 0.98 [0.77–1.25] 1.01 [0.67–1.51]
a) significance test: Pearson Chi-square test, ns= not significant (p < 0.05), ns = not significant (p > 0.05)
b) Multilevel logistic regression, odds ratios are corrected for age, sex, educational level, type of health insurance, residence, smoking, alcohol 
consumption and exercising
c) reference in multilevel logistic regression is BMI < 25
* p < 0.05BMC Family Practice 2006, 7:43 http://www.biomedcentral.com/1471-2296/7/43
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being more successful than others [43-45]. As such, there
still seems to be need for good weight management sys-
tems in general practice and for methods with long-term
effects. First of all, it seems important that GP acknowl-
edge their role in weight management more than they cur-
rently do. GPs tend to conceptualise obesity in terms of
responsibility and they consider weight management to
be the patient's responsibility [46]. As such GPs do not
think that weight management is within their profes-
sional domain. However, given the results of the present
and other studies [24,29,30,47] it would be worthwhile if
GPs should become aware of the important role they
potentially can have in weight management and related
health care use. This is especially true for countries like the
Netherlands where GPs function as gatekeepers and usu-
ally are the first professionals confronted with health care
problems of their patients.
Conclusion
Obesity and, to a lesser extent, moderate overweight,
increase the workload of Dutch general practitioners and
the use of prescribed medication. The current expansion
in the prevalence of obesity will further increase the use of
health care and related costs, especially for diseases of the
endocrine system, the cardiovascular system, and the
musculoskeletal system. This prompted the National
Health Council of the Netherlands to urge for further
examination of effective prevention strategies in this area.
Since a large majority of all Dutch persons visit their GP
over the course of a year, GPs' potential role in prevention
strategies cannot be denied.
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